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Introduction {#sec005}
============

Drug development is facilitated by understanding of the interactions between tumors and microenvironments. Preclinical models enhance knowledge of tumor biology and drug development to elucidate drug resistant mechanisms of tumors. Appropriate selection of preclinical models is pivotal to bridge the translational gap between drug development and clinical application.

Triple negative breast cancer (TNBC) tumors lack expression of estrogen receptor (ER), progesterone receptor (PR), and human epithelial growth factor receptor 2 (HER2). Compared to hormone receptor-positive breast cancer, TNBC exhibits aggressive clinical characteristics \[[@pone.0225082.ref001]\]. Cytotoxic chemotherapy is the only systemic treatment option to manage TNBC, because of a lack of effective target therapy \[[@pone.0225082.ref002]\].

Pharmaceutical companies have invested in research and development (R&D) to find an effective target therapy. However, many hurdles block the development of new drugs, including the significant cost in terms of money and time. In 2000, the R&D cost per new drug, including the pre-clinical and clinical cost was, on average US 802 million dollars \[[@pone.0225082.ref003]\]. The mean duration of the clinical and approval phase, from investigational new drug application filing to new drug application submission and approval, was 87.4 months \[[@pone.0225082.ref004]\]. Although new agents have been discovered, the successful clinical trial process is difficult \[[@pone.0225082.ref005]\]. A new strategy for successful clinical trial is necessary to overcome these challenges \[[@pone.0225082.ref006]\].

Drug sensitivity tests can be performed in in vitro models \[[@pone.0225082.ref007]\] whereby cancer cells are directly exposed to various drug combinations in multiple concentrations. This kind of study is considered a basic experiment before further evaluations of the drug can be tested in clinical trials \[[@pone.0225082.ref008]\]. However, even well-designed artificial conditions for cancer cell lines do not directly reflect patients' micro-environments \[[@pone.0225082.ref009], [@pone.0225082.ref010]\].

Mouse models, or in vivo models, use patient-derived cancer cells to induce tumors in mice. Animal models can simulate interaction between tumors and the microenvironment \[[@pone.0225082.ref011], [@pone.0225082.ref012]\]. However, in vivo models which use cultured cancer cells of in vitro studies have the same limitation because they also do not accurately reflect the characteristics of a patient's primary tumor \[[@pone.0225082.ref013]--[@pone.0225082.ref015]\].

Patient-derived xenograft (PDX) models which use immune-compromised mice implanted with fresh tumor tissue from patients with cancer have been introduced as new in vivo models for cancer research \[[@pone.0225082.ref016], [@pone.0225082.ref017]\]. In general, tumors in PDX models have shown similar histopathological features as primary tumors \[[@pone.0225082.ref018]\]. Therefore, theoretically, PDX models can predict drug response of primary tumors better than conventional in vivo or in vitro models \[[@pone.0225082.ref019]--[@pone.0225082.ref021]\].

Patient-derived xenograft models have been established for several cancer types \[[@pone.0225082.ref022]--[@pone.0225082.ref025]\] and successful take rates of PDX models vary according to cancer type. Previous studies have reported 10--50% success rates of PDX models in colon, pancreas, lung, prostate, and breast cancer \[[@pone.0225082.ref026]\]. To enhance successful engraftment and maintenance of PDX models, it is crucial to characterize the factors influencing the establishment of PDX models, but little is known about those factors.

The current study focused on the establishment of PDX models of breast cancer and identifying the influencing factors for successful engraftment of the models. Furthermore, in vivo chemosensitivity tests were performed in the PDX models with TNBC, with and without highly aggressive diseases characteristics, and BRCAness.

Materials and methods {#sec006}
=====================

Patients and subtypes {#sec007}
---------------------

A total of 82 patients with breast cancer were enrolled in this study. One patient who received serial biopsies including a preoperative needle biopsy and surgical resection before (BR30) and after (BR40) neoadjuvant chemotherapy was also included. Thus, a total of 83 malignant tumors of breast were used to develop PDX models in the study. All patients underwent breast surgery or biopsy at Severance Hospital, Seoul, Korea. Fresh tumor tissue was obtained during surgery or biopsy. After removal, tumor tissue was immediately transferred to the animal laboratory (Avison Biomedical Research Center, Seoul, Korea). Cubic tissue of 3mm^3^ in size was minced and directly implanted into mice without delay. We attempted to establish PDX models from TNBC (n = 65), luminal A or B (n = 13), and HER2 positive (n = 5) breast cancer patients. Among TNBC patients, 39 received neoadjuvant chemotherapy.

PDX models and establishment periods {#sec008}
------------------------------------

Tumor tissue was implanted into the subcutaneous or mammary fat pad of 6 to 12-week-old female NOG (NOD.Cg-Prkdcscid Il2rgtm1Sug) mice \[[@pone.0225082.ref027]\]. Tumor size was measured using calipers once a week, and tumor volume was calculated as 0.5 × Length × Width^2^\[[@pone.0225082.ref028]\]. When the tumor volume reached 1500 mm^3^-, the implanted tumor was harvested from the mice under isoflurane anesthesia \[[@pone.0225082.ref026]\]. A portion of the tumor (\~5mm^3^) was engrafted in a new generation of mice \[[@pone.0225082.ref029]\]. The remaining tumor was cut into pieces and stored in liquid nitrogen. The tumor tissue was stored in a solution of 90% fetal bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO) for use in re-engraftment. Some of the tumor tissues were stored frozen for generating sequencing data \[[@pone.0225082.ref030]\]. Primary tumor was implanted into the first generation of mice, which was defined as F1 mice. The harvested tumor was serially implanted into second- (F2) and third-generation (F3) of mice. When the PDX model had been engrafted into third generation of mice, it was considered a successful PDX model \[[@pone.0225082.ref031]\].

Establishment periods from F1 to F3 (F1-F3) were measured. The establishment period was divided into establishment periods from F1 to F2 (F1-F2) and F2 to F3 (F2-F3), and compared. Establishment periods from F1 to F3 (F1-F3) was not exceeded 550 days.

Animal care {#sec009}
-----------

All animal experiments were performed in a facility accredited by AAALAC International (\#001071) in accordance with Guide for the Care and Use of Laboratory Animals 8th edition, NRC (2010). The tumor implanted mice were housed in one cage (maximum five mice). Food was exchanged once a week and water was supplied automatically from the automatic water supply equipment. A facility staff of animal laboratory periodically checked the status of mice. Mice monitoring was performed once a week. After tumor implantation, euthanasia was performed when tumors reached 1500mm^3^ in volume or became ulcerated, tumors affected physiological functions including gait, posture, ability to eat/drink/urinate/defecate, or when mice lost more than 15% of their first body weight. Mice were euthanized by CO2 gas inhalation in accordance with the humane endpoints which included the above descriptions. And when the mice reached endpoint criteria, we performed euthanasia by CO2 gas inhalation within 2 days. In our study, there were no mice which died before meeting criteria for euthanasia. There are well-trained facility staffs who can help to solve the problem in animal care at our institution. They advised injection methods of drugs (carboplatin/olaparib).

Histopathological confirmation {#sec010}
------------------------------

When a tumor was engrafted to a new mouse, one piece of tumor tissue (\~8mm^3^) was used to construct FFPE (Formalin fixed paraffin embedded) blocks. Immunohistochemistry analysis was performed to confirm the histopathological similarity including ER, PR, and HER2 between primary tumor and those in PDX models. Xylene and serial concentrations of ethanol were used for deparaffinization and hydration of tumor sections. For antigen retrieval and blocking endogenous peroxidases, a solution of 0.4% H~2~O~2~ and 10mM sodium citrate buffer (pH6.0) was used. Sections were treated with a peroxidase-conjugated polymer solution (Dako REAL EnVision Detection System, Peroxides/DAB+, antibodies of Rabbit/Mouse). Primary antibodies used for in immunohistochemistry analysis included ERα (clone SP1, 1:100 dilution, LifeSpan BioSciences, Seattle, WA, USA); PR (clone 1E2, 1:100 dilution, ABCAM, Cambridge, CB4 0FL, UK), HER2 (clone EP1045Y, 1:100 dilution, ABCAM, Cambridge, CB4 0FL, UK) and Ki67 (clone EPR3610, 1:500 dilution, ABCAM, Cambridge, CB4 0FL, UK). A pathologist confirmed all stained slides.

Factors relating to success of PDX models {#sec011}
-----------------------------------------

Clinicopathological factors relating to the successful engraftment of PDX models were analyzed. These factors included age, T-stage, nodal status, hormone receptor status, HER2 status, Ki67 level, breast cancer subtype, histologic grade, treatment status, biopsy method (surgery or needle biopsy), engraftment period, mouse type, TNM Classification of Malignant Tumours (TNM) stage, existence/absence of *BRCA* mutation, and survival status of patient. Disease burden was analyzed. Aggressive diseases were defined as progressive diseases during preoperative or neoadjuvant chemotherapy, recurrent, and metastatic diseases.

Chemosensitivity tests using the PDX models {#sec012}
-------------------------------------------

We performed chemosensitivity tests using three PDX models including a tumor from TNBC with a novel germline pathogenic *BRCA1* mutation, c.5339T-\>C; p.Leu1780Pro; rs80357474 (L1780P), which was introduced in our previous study \[[@pone.0225082.ref032]\], a tumor from TNBC with a germline *BRCA1* deleterious mutation, c.3277delG; p.Val1093SerfsTer16; rs113900085, and a tumor from a TNBC without germline pathogenic *BRCA* mutation. PDX models were derived from patients who had BRCA1 mutation (n = 2, L1780P and rs113900085) and the wild type of BRCA1 (n = 1). Each model comprised nine mice, which were divided equally into three groups (1 group = 3 mouse, vehicle \[PBS\], olaparib, and carboplatin.). A total of 27 mice were used in the chemosensitivity tests.

Dosages of olarparib and carboplatin were 50 mg/kg and 25 mg/kg, respectively \[[@pone.0225082.ref033], [@pone.0225082.ref034]\]. Olaparib was administrated via intraperitoneal injection for 28 consecutive days. Carboplatin was administrated via intraperitoneal injection once a week. Duration of the *in vivo* test was not exceeded 2 months. Tumor volumes were measured using the below equation, Volume = 0.5 × Length × Width^2^

Sequencing analysis of the PDX model with L1780P {#sec013}
------------------------------------------------

Whole genome sequencing (WGS) and whole exome sequencing (WES) of one PDX model with L1780P mutation were performed in collaboration with the Theragen company (Seoul, Korea). The depth of WGS was 30X in buffy coat, 60X in primary tumor, and 30X in F1, F2, and F3, respectively. WES was only performed in the primary tumor, and the depth of WES was 250X.

Using the TruSeq Nano DNA Sample Preparation Kit from Illumina (San Diego, CA), DNA sequencing libraries of WGS were constructed, according to the manufacturer protocol. Quality of the amplified libraries was confirmed by electrophoresis on Agilent Bioanalyzer High Sensitivity DNA Kit (part \# 5067--4626) (Agilent, CA). The libraries were sequenced using Illumina HiSeq2500 and Cluster generation. Then, 2 × 100 cycle sequencing reads, separated by paired-end turnaround, were performed on the instrument using HiSeq Rapid SBS Kit v2 (FC-402-4021) and HiSeq Rapid PE Cluster Kit v2 (PE-402-4002; Illumina, CA).

In the WES, the quality and quantity of purified DNA were assessed by fluorometry (Qubit, Invitrogen) and gel electrophoresis, and the sample was hybridized with RNA probes, SureSelect XT Human All Exon V5 Capture library. The captured targets were then pulled down by biotinylated probe/target hybrids using streptavidin-coated magnetic beads (Dynabeads My One Streptavidine T1; Life Technologies Ltd.). The resulting purified libraries were applied to an Illumina flow cell for cluster generation and sequenced using 100 bp paired-end reads on an Illumina Hiseq2500 sequencer, following the manufacturer\'s protocols.

The quality of reads in the WGS and WES were confirmed using fastQC (v.0.10.1) \[[@pone.0225082.ref035]\], which also expounded the basic quality for sequence quality score, GC content, N content, length of distribution, and duplication levels. After examining the read quality, the low-quality bases below Q20 were trimmed using Cutadapt (v.1.8.1) \[[@pone.0225082.ref036]\].

In order to remove mouse reads in PDX samples, BBMap \[[@pone.0225082.ref037]\] was applied to the fastq files based on hg19 and Ensembl Release 77 reference genome for human and mouse, respectively. Only reads that were classified as human reads were then analyzed.

Statistics and ethics {#sec014}
---------------------

The SPSS statistics program version 23 (International Business Machines Crop., Armonk, NY, USA) was used for all analyses. Categorical variables were examined using chi-square test or Fisher's exact test. Continuous variables were examined using student T-test. Multivariate analyses were examined using binary regression models. Multivariate analyses were adjusted for significant factors in univariate analyses. All statistical analyses were two-sided and p-values of less than 0.05 were considered statistically significant.

All tumor tissue was obtained with the patient's written consent and the informed written consent was provided by the patients. All procedures were approved by the Institutional Review Board of Yonsei University Health System (IRB No.4-2012-0705). All experiments were approved by the Institutional Animal Care and Use Committee in Yonsei University Hospital System (YUHS-IACUC) and animals were maintained in a facility accredited by AAALAC International (\#001071) in accordance with Guide for the Care and Use of Laboratory Animals 8th edition, NRC (2010).

Results {#sec015}
=======

Of the 83 tumor samples, most tumor tissue (65 out of 83 samples) came from TNBC patients ([Fig 1A](#pone.0225082.g001){ref-type="fig"}). Only one tumor sample was subcutaneously implanted into mice. 78 tumors were implanted into mammary fat pads. Successful engraftments of PDX models were established in 19 TNBC cases. All successful engraftments of PDX models were implanted into mammary fat pads. We attempted to establish PDX models from residual tumors more than primary tumors ([Fig 1B](#pone.0225082.g001){ref-type="fig"}). The overall success rates of PDX models were higher in cases with primary TNBCs than those in residual TNBCs (38.5% for primary TNBC vs. 23.1% for residual TNBCs) ([Fig 1B](#pone.0225082.g001){ref-type="fig"}). We established a PDX model with a novel germline pathogenic mutation of BRCA1, L1780P (Patent pending, reference number; DPB172272).

![Proportions of successful engraftment of PDX models.\
**(**A) Proportion of breast cancer subtypes. (B) Successful engraftment of PDX models were derived from TNBC patient with or without neoadjuvant chemotherapy.](pone.0225082.g001){#pone.0225082.g001}

A total of 21 successful PDX models were derived from TNBC patients. Of those, two cases were classified as developed lymphoma. Except for those two cases, 19 tumors from PDX models coincided with the histopathological characteristics of primary tumors ([Fig 2A](#pone.0225082.g002){ref-type="fig"}). Immunohistochemistry revealed Ki67 expression in the PDX models [Fig 2B](#pone.0225082.g002){ref-type="fig"}. ER, PR, and HER2 tumor samples were positive controls. ([Fig 2C](#pone.0225082.g002){ref-type="fig"})

![Histopathological characteristics of successful engraftment of PDX models and patients.\
(A) H&E staining and immunohistochemistry of PDX models and primary tumor of patients. (B) Ki67 expression of PDX models. (C) Positive control of ER, PR and HER2 in immunohistochemistry.](pone.0225082.g002){#pone.0225082.g002}

The establishment periods of F1-F3 interval are shown in [Fig 3A](#pone.0225082.g003){ref-type="fig"}. The median establishment period from F1 to F3 was 221 days (range 93--550 days). The PDX models of residual TNBC with neoadjuvant chemotherapy (Neo TNBC) showed shorter establishment periods than primary TNBC (p = 0.02; [Fig 3B](#pone.0225082.g003){ref-type="fig"}). The F2-F3 interval was significantly shorter than the F1-F2 interval (p = 0.00002; [Fig 3B](#pone.0225082.g003){ref-type="fig"}). The shortest interval of establishment period was the F2-F3 interval of Neo TNBC models (median 62 days, range 41--158 days; [Fig 3B](#pone.0225082.g003){ref-type="fig"}).

![Successful engraftment of F1 to F3 in PDX models.\
(A) Establishment periods of all successful PDX models (B) F1-F2 and F1-F3 intervals according to status of neoadjuvant chemotherapy.](pone.0225082.g003){#pone.0225082.g003}

In univariate analysis, T-stage, histologic grade, estrogen receptor status, and Ki67 levels were statistically significant (p\<0.05) ([Table 1](#pone.0225082.t001){ref-type="table"}). Presence of BRCA mutation, aggressive diseases status, or death were related to successful PDX models (p\<0.05). Hormone and HER2 positive cases made up a small portion of total cases (n = 18, 21.7%), and the results were not significant in hormone and HER2 positive cases. All successful PDX models were made from TNBC and Neo TNBC cases.

10.1371/journal.pone.0225082.t001

###### Analysis of factors related to PDX models.

![](pone.0225082.t001){#pone.0225082.t001g}

  Factors                                                        PDX status                                     
  -------------------------------------------------------------- ------------------- ------------ ------------- -------
  **Age (years)**                                                **\<60**            43 (67.2%)   14 (73.7%)    0.592
  **≥60**                                                        21 (32.8%)          5 (26.3%)                  
  **T stage**                                                    **-T1**             34 (56.7%)   5 (26.3%)     0.038
  **T2**                                                         22 (36.7%)          10 (52.6%)                 
  **T3-T4**                                                      4 (6.7%)            4 (21.1%)                  
  **Nodal status**                                               **Negative**        40 (65.6%)   8 (47.1%)     0.165
  **Positive**                                                   21 (34.4%)          9 (52.9%)                  
  **Histologic grade**                                           **I/II**            33 (56.9%)   3 (15.8%)     0.002
  **III**                                                        25 (43.1%)          16 (84.2%)                 
  **ER**                                                         **Negative**        51 (79.7%)   19 (100.0%)   0.032
  **Positive**                                                   13 (20.3%)          0 (0.0%)                   
  **PR**                                                         **Negative**        55 (85.9%)   19 (100.0%)   0.083
  **Positive**                                                   9 (14.1%)           0 (0.0%)                   
  **HER2**                                                       **Negative**        56 (87.5%)   19 (100.0%)   0.105
  **Positive**                                                   8 (12.5%)           0 (0.0%)                   
  **Ki67 (%, n = 79)**                                           **\<39 (n = 41)**   38 (62.3%)   3 (16.7%)     0.001
  **≥39 (n = 38)**                                               23 (37.7%)          15 (83.3%)                 
  **BRCA mutation**                                              **Absent**          61(96.9%)    15(78.9%)     0.005
  **Present**                                                    2(3.1%)             4(21.1%)                   
  **Survival status**                                            **Live**            62(96.9%)    15(78.9%)     0.008
  **Death**                                                      2(3.1%)             4(21.1%)                   
  **Aggressive diseases**[\*](#t001fn002){ref-type="table-fn"}   **Absent**          54 (87.5%)   10 (63.2%)    0.004
  **Present**                                                    10 (12.5%)          9 (36.8%)                  

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; Ki67: cell proliferation index

\* Aggressive diseases were considered to be progressive diseases during neoadjuvant chemotherapy, recurrent, and metastatic disease

In 65 TNBC cases, histologic grade, Ki67 level, presence of BRCA mutation, aggressive diseases status, and death were statistically significant on univariate analysis (p\<0.05; [Table 2](#pone.0225082.t002){ref-type="table"}).

10.1371/journal.pone.0225082.t002

###### Analysis of factors related to TNBC PDX models.

![](pone.0225082.t002){#pone.0225082.t002g}

  Factors                                                        PDX status                                    
  -------------------------------------------------------------- ------------------- ------------ ------------ -------
  **Age(years)**                                                 **\<60**            29 (63.0%)   14 (73.7%)   0.410
  **≥60**                                                        17 (37.0%)          5 (26.3%)                 
  **T stage**                                                    **-T1**             24 (54.5%)   5 (26.3%)    0.070
  **T2**                                                         17 (38.6%)          10 (52.6%)                
  **T3-T4**                                                      3 (6.8%)            4 (21.1%)                 
  **Nodal status**                                               **Negative**        28 (63.6%)   8 (47.1%)    0.238
  **Positive**                                                   16 (36.4%)          9 (52.9%)                 
  **Histologic grade**                                           **I/II**            19 (45.2%)   3 (15.8%)    0.027
  **III**                                                        23 (54.8%)          16 (84.2%)                
  **Ki67 (%, n = 79)**                                           **\<39 (n = 41)**   23 (52.3%)   3 (16.7%)    0.010
  **≥39 (n = 38)**                                               21 (47.7%)          15 (83.3%)                
  **BRCA mutation**                                              **Absent**          43(93.5%)    14(73.7%)    0.027
  **Present**                                                    3(6.5%)             5(26.3%)                  
  **Survival status**                                            **Live**            44(95.7%)    15(78.9%)    0.034
  **Death**                                                      2(4.3%)             4(21.1%)                  
  **Aggressive diseases**[\*](#t002fn002){ref-type="table-fn"}   **Absent**          37 (80.4%)   10 (52.6%)   0.023
  **Present**                                                    9 (19.6%)           9 (47.4%)                 

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; Ki67: cell proliferation index

\* Aggressive diseases were considered to be progressive diseases during neoadjuvant chemotherapy, recurrent, and metastatic disease

Tumor size was not significant in TNBC cases (p\>0.05). In TNBC cases with neoadjuvant chemotherapy, histologic grade, presence of BRCA mutation, aggressive diseases status, and death were statistically significant (p\<0.05) ([Table 3](#pone.0225082.t003){ref-type="table"}). Information of the chemotherapy regimens is presented in [S1 Table](#pone.0225082.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0225082.t003

###### Analysis of factors related to TNBC PDX models with neoadjuvant chemotherapy.

![](pone.0225082.t003){#pone.0225082.t003g}

  Factors                                                        PDX status                                   
  -------------------------------------------------------------- ------------------- ------------ ----------- -------
  **Age(years)**                                                 **\<60**            22 (73.3%)   8 (88.9%)   0.331
  **≥60**                                                        8 (26.7%)           1 (11.1%)                
  **T stage**                                                    **-T1**             13 (44.8%)   2 (22.2%)   0.066
  **T2**                                                         13 (44.8%)          3 (33.3%)                
  **T3-T4**                                                      3 (10.3%)           4 (44.4%)                
  **Nodal status**                                               **Negative**        16 (55.2%)   2 (25.0%)   0.131
  **Positive**                                                   13 (44.8%)          6 (75.0%)                
  **Histologic grade**                                           **I/II**            16 (59.3%)   1 (11.1%)   0.012
  **III**                                                        11 (40.7%)          8 (88.9%)                
  **Ki67 (%, n = 79)**                                           **\<39 (n = 41)**   17 (58.6%)   2 (22.2%)   0.056
  **≥39 (n = 38)**                                               12 (41.4%)          7 (77.8%)                
  **BRCA mutation**                                              **Absent**          28(93.3%)    6(66.7%)    0.036
  **Present**                                                    2(6.7%)             3(33.3%)                 
  **Survival status**                                            **Live**            28(93.3%)    6(66.7%)    0.036
  **Death**                                                      2(6.7%)             3(33.3%)                 
  **Aggressive diseases**[\*](#t003fn002){ref-type="table-fn"}   **Absent**          23 (76.7%)   2 (22.2%)   0.003
  **Present**                                                    7 (23.3%)           7(77.8%)                 

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; Ki67: cell proliferation index

\* Aggressive diseases were considered to be progressive diseases during neoadjuvant chemotherapy, recurrent, and metastatic disease

Multivariate analyses showed poor histologic grade and aggressive diseases status were independently associated with the successful engraftment of PDX models (p\<0.05; [Table 4](#pone.0225082.t004){ref-type="table"}), and presence of BRCA mutation and death event were marginally associated with successful engraftment of PDX models (p = 0.05; [Table 4](#pone.0225082.t004){ref-type="table"}).

10.1371/journal.pone.0225082.t004

###### Multivariate analysis of factors relating to successful engraftment of PDX models.

![](pone.0225082.t004){#pone.0225082.t004g}

  ---------------------------------------------------------------------------------------------------------------------------------
                                                 Factors                               *p*-value   OR              95% C.I.
  ---------------------------------------------- ------------------------------------- ----------- --------------- ----------------
  **All cases**\                                 **Histologic grade (I/II vs. III)**   0.004       7.040           1.847--26.836
  **(n = 83)**                                                                                                     

  **BRCA mutation (absent vs. present)**         0.012                                 7.262       1.549--34.034   

  **Survival status (live vs. Death)**           0.021                                 8.247       1.382--49.444   

  **Aggressive diseases (absent vs. present)**   0.006                                 4.860       1.577--14.974   

  **TNBC cases**\                                **Histologic grade (I/II vs. III)**   0.034       4.406           1.114--17.420
  **(n = 65)**                                                                                                     

  **BRCA mutation (absent vs. present)**         0.039                                 5.119       1.083--24.196   

  **Survival status (live vs. Death)**           0.053                                 5.867       0.974--35.339   

  **Aggressive diseases (absent vs. present)**   0.027                                 3.700       1.162--11.783   

  **Neo TNBC cases**\                            **Histologic grade (I/II vs. III)**   0.030       11.636          1.269--106.719
  **(n = 39)**                                                                                                     

  **BRCA mutation (absent vs. present)**         0.056                                 7.000       0.952--51.448   

  **Survival status (live vs. Death)**           0.056                                 7.000       0.952-51-448    

  **Aggressive diseases (absent vs. present)**   0.007                                 11.500      1.930--68.518   
  ---------------------------------------------------------------------------------------------------------------------------------

In the chemosensitivity tests, there were no significant differences in the average tumor volume of the three treatment arms in PDX models with wild type *BRCA1* and the deleterious *BRCA1* mutation. However, nearly complete remission in the carboplatin arm and partial remission in the olaparib arm were attained in the PDX model with the novel L1780P *BRCA1* mutation ([Fig 4A--4E](#pone.0225082.g004){ref-type="fig"}).

![Scheme and results of chemosensitivity tests using PDX models.\
(A) PDX models were derived from patients who had BRCA1 mutation (n = 2) or wild-type BRCA1 (n = 1). Each model comprise nine mice, which were divided into three groups (1 group = 3 mouse, two single treatment groups and one vehicle group). (B-E) When implanted tumor reached an average size of 200--250 mm^3^ (Volume = 0.5×Length×Width\^2), the chemosensitivity test was performed. Olaparib (50mg/kg, once a daily) and carboplatin (25mg/kg, once a weekly) were administered by an intra-peritoneal (i.p.) route. Phosphate buffered saline was used to as a vehicle.](pone.0225082.g004){#pone.0225082.g004}

In WGS, c.5339T\>C, L1780P in *BRCA1* was continuously detected in buffy coat, primary tumor, F1, F2, and F3 tumors. However, variant allele frequency (VAF) was increased in late passage. (Normal = 0.53, F0 = 0.63, F1 = 0.9, F2 = 1.0, F3 = 1.0). There was no pathogenic germline mutation in buffy coat, primary tumor and PDX models, other than in L1780P in WGS. In TCGA data, there was no c.5339T\>C, L1780P variant among in *BRCA1* mutations.\[[@pone.0225082.ref038]\] When we investigated the L1780P mutation in a Korean database reported in a previous study, there was no L1780P mutation in the normal population. \[[@pone.0225082.ref032]\]

Discussion {#sec016}
==========

We demonstrated that the successful establishment of PDX models from TNBC patients is related to poor clinicopathologic factors including large tumor size, poor histologic grade, and aggressive diseases status at the time of tissue sampling. Aggressive diseases, including progressive diseases during neoadjuvant chemotherapy, recurrent disease, and metastatic disease at presentation, were associated with the establishment of successful PDX models on multivariate analysis. A previous study reported that TNBC patients with progressive disease during neoadjuvant chemotherapy had higher xenograft take rate than those with stable diseases or partial response after neoadjuvant chemotherapy (6 of 7 patients, 85.7% vs. 5 of 17 patients, 29.4%) \[[@pone.0225082.ref039]\]. These findings were similar to our findings. Therefore, tumor tissue from patients with TNBC with aggressive features may be the best candidate for establishing PDX models.

Large tumor size and poor histologic grade were significantly related to stable take rates in successful PDX models. A previous study reported that large tumor size and grade were associated with successful engraftment of PDX in bladder cancer \[[@pone.0225082.ref040]\]. Similar results have also been reported in pancreatic cancer where large tumor size (≥T3) was shown to be related to successful engraftment of PDX \[[@pone.0225082.ref041]\]. These studies suggested that large tumor size and poor histologic grade are predictors of successful engraftment of PDX, and this is concordant with our results. The analysis of factors related to the successful engraftment of PDX is crucial because considerable time and funds are consumed making successful PDX models. When developing PDX models, the more suitable the patients enrolled are, the less time and funds are required in order to achieve engraftment. The results of this study will be helpful to improve pre-clinical research. Furthermore, genomic research and drug tests in successful PDX models are necessary to improve the performance of PDX models.

In the current study, the mean F1-F2 interval was longer than the mean F2-F3 interval. In concordance with our results, a previous publication also demonstrated that the F1-F2 interval was longer than the F2-F3 interval in successful breast cancer PDX models \[[@pone.0225082.ref039]\].

In this study, Neo TNBC PDX models had shorter establishment period intervals than TNBC PDX models. These results suggested that shorter establishment period may be due to the aggressive nature of residual tumors after neoadjuvant chemotherapy, compared to primary tumors \[[@pone.0225082.ref042]\]. Aggressiveness of tumors has been shown to affect the successful establishment of PDX models and the rapid formation of tumor and tumor growth in the immune-deficient mouse \[[@pone.0225082.ref043], [@pone.0225082.ref044]\]. It was concordant with our study. Thus, in terms of establishment periods for establishing PDX models, residual TNBC after neoadjuvant chemotherapy may be more suitable than primary tumor of TNBC.

Chemosensitivity tests using PDX models were introduced by previous studies \[[@pone.0225082.ref045]--[@pone.0225082.ref047]\]. However, only a few studies reported chemosensitivity tests using PDX models from residual breast cancer after chemotherapy \[[@pone.0225082.ref048]\]. It has been suggested that BRCA mutations or BRCAness are potential targets of PARP inhibitors and platinum agents \[[@pone.0225082.ref033], [@pone.0225082.ref049]\]. Thus, we performed in vivo chemosensitivity tests of PARP inhibitor, olaparib and platinum agent, carboplatin, for PDX models with residual TNBC with/without BRCA1 mutation. A potential benefit from olaparib and carboplatin was evident in the PDX model with the L1780P mutation, but not in the other models. The establishment periods of PDX models remains a major challenge to applying them as in vivo chemosensitivity tests or the baseline study of N-of-1 trials. To overcome this hurdle, appropriate selection criteria for enrollment of patients for the PDX models should be considered. In this study, the median establishment period was 8 months. A limitation of this study is that chemosensitivity tests of the PDX models with L1780P mutation were performed in a single PDX model of one patient. Because the current study was conducted as an initial step of proof-of-concept study of N-of-1 trial, the results provide additional information about the potential application of chemosensitivity tests using PDX models. More chemosensitivity tests of PDX models for a larger number of L1780P mutation cases may strengthen the implications of further investigations of BRCA1 L1780P mutation olaparib and carboplatin drug-sensitivity.

In the current study, histopathological characteristics of tumors in successful PDX models were concordant with primary tumors. Interestingly, the sequencing analyses for the PDX model with L1780P mutation showed the VAF of the mutation was different among passages. This suggests that genetic alteration may occur throughout the passages. However, full genomic analyses were not performed in either primary tumors or successful PDX models---which was a limitation of this study. One of the advantages of PDX models is their ability to reflect patients' genomic and clinicopathologic characteristics. Therefore, sequencing data from patients and PDX models is essential to examine the similarity of the genomic landscape between the two \[[@pone.0225082.ref048], [@pone.0225082.ref050], [@pone.0225082.ref051]\].

PDX models often utilize immune deficient mouse to avoid rejection of the human tumor graft by the mouse immune system. For this reason, PDX models using immune deficient mouse cannot reflect crosstalk of the immune system and human tumors. A previous study introduced a PDX model using humanized mice that was developed by injection of human hematopoietic cells into the mice to overcome this limitation of PDX models using immune deficient mice. \[[@pone.0225082.ref052], [@pone.0225082.ref053]\]

In further studies, it will be necessary to perform genomic sequencing and analysis of sequencing data in all successful PDX models. Additional experiments are necessary for the two suspected lymphoma to evaluate the mechanism of formation of lymphoma in PDX models \[[@pone.0225082.ref054]\].

Conclusions {#sec017}
===========

The current study showed the feasibility of establishing PDX models using residual TNBC after neoadjuvant chemotherapy. Patients who have aggressive diseases status, large tumors, and poor histologic grade are ideal candidates for developing successful PDX models. This study also showed the potential usefulness of in vivo chemosensitivity tests for tumors with targetable biomarkers, particularly tumors with a novel pathologic mutation, L1780P. Further genomic analyses of the PDX models may shed light on tumor progression and drug resistant mechanisms in TNBC.

Supporting information {#sec018}
======================

###### Information on the chemotherapy regimens in the patients for application of PDX establishment.

(XLSX)

###### 

Click here for additional data file.

A part of the abstract of the study was presented in the poster session at the Global Academic Programs (Gap) conference, 2018, Stockholm, Sweden.
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Reviewer \#1:

This manuscript is a report of the successful development and characterization of a set of TNBC PDXs. The development of these models provide a good resource for other researchers interested in TNBC. There is not very much new information presented within these studies; it is well known that tumor growth rates increase after the first successful passage in vivo, which is the focus of 3 of the figures.

Comments that should be addressed :

1\. It would be helpful to state if this PDX cohort are all from Asians, as this could provide a unique resource for other researchers. Along these lines, it would be very informative to know if any of these PDXs are available to other researchers, and if so, this should be stated.

\- A process of our PDX model is now on patenting. When the patent process is completed, we would like to provide our PDX models to other researchers.

2\. A more descriptive title highlighting the interesting aspect of the manuscript is needed.

\- We revised the title as establishment and chemosensitivity test in triple negative and BRCA mutated breast cancer patient-derived xenograft models.

3\. Figure 2A is poorly produced, the text should fit within the graph.

\- Thank you for your comment. We added a new figure and revised the text.

4\. The quality of the H&Es and ER/PR/HER2 IHC from the PDXs is very poor, and new pictures should be taken prior to publication. Positive controls for ER/PR/HER2 are always helpful to confirm that the assay is properly working and that the samples highlighted are truly TNBC.

\- Positive control of ER, PR and HER2 was added and new pictures of IHC were placed.

5\. If would be helpful to know if the BRCA1 mutation (L1780P) is found in existing patient datasets (TCGA), and if not, this should be stated.

\- When we looked at the TCGA data, there was no L1780P mutation in BRCA1. It was described in results. We looked at the L1780P mutation in the Korean database. There was no L1780P mutation in normal population.(1)

6\. The timing of when the carboplatin was administered to the mice (size of tumor at the start of treatment) should be added to the graphs or the text.

\- When tumor reached average size of 200-250㎣, drug (carboplatin or olaparib) administered to mice. This was described in the legend of figure 4.

Reviewer \#2:

The manuscript from Park et al. entitled \"Chemosensitivity test in triple negative breast cancer patient-derived xenograft model\" investigate the factors influencing the establishment of patient derived xenograft models of triple negative breast cancer. The authors successfully generate 19 TNBC PDX and tested carboplatin versus olaparib treatment in 1 wild-type PDX versus 2 with BRCA1 mutation. They also describe a new BRCA1 mutation which sensitize the PDX to carboplatin treatment.

Establishing better in vivo models to acquire strong and valid pre-clinical data is of major importance in Oncology. The work presented here from Park at al. is therefore definitely suitable for publication in PLOS-ONE, however, some major points need to be adjusted before publication.

Major comments:

A few important caveats should be added to the discussion. First, the fact that more aggressive tumors are more likely to generate PDX is quite obvious but one should mention that for this reason, the cohort of PDX used to model TNBC are biased toward more aggressive tumors and do not recapitulated the variety of a human cohort. Moreover, even if primary TNBC have a lower success rate, they are also very interesting and suitable for drug studies and should be consider to design pre-clinical studies, not just the neo TNBC.

\- Thank you for your comment. It is necessary to establish the PDX model from hormone and HER2 positive patients. The figure 1 presented that we attempted to establish the PDX model from hormone and HER2 positive patients. Recently, one PDX model was successfully established from ER, PR and HER2 positive breast cancer patient. (Data not shown) To make successful establishment of PDX models from hormone and HER2 positive patients will be continue.

We agreed with your opinion. We are planning to conduct additional pre-clinical study which uses the suitable drug treatment for primary TNBC without neoadjuvant chemotherapy will be performed in the near future.

Second, because of the nature of PDX and the use of immune deficient mice, it is important to remember that most of the tumor micro environment and interaction to the immune system is missing. The authors should therefore improve their discussion.

\- We agreed your opinion. Using the immune deficient mice was major limitation of our PDX models. We described it in discussion.

The authors state that their TNBC PDX are suitable models to test alterative treatment strategies. However, only conventional treatment is presented here. It will have been nice to see new therapies or maybe some combination with irradiation.

\- When we started this pre-clinical study, olaparib and carboplatin were not indicated to tumors with germline BRCA1 mutation. That's why we only treated monotherapy for our PDX models. As you stated, we agree that the combination treatment with/without irradiation can be a good alternative treatment option for TNBC. These new regimens will be tested in the further study.

Minor comments:

\- The authors should pay attention to the manuscript organization. The figure legends should be grouped at the end and precisely describe the figure without including material and methods data. The figures should be organized in one page. Meaning each panel, like 4A 4B should be presented in one page and have a common legend.

\- Thank you for your comment. Figure 4A and 4B were presented in one page and described a common legend.

\- In the first paragraph, please state how may primary and residual TNBC you have in your study, not just the success rate.

\- In TNBC patients, 26 primary tumors and 39 residual tumors were used to establishment of PDX models. This was described in materials and methods.

\- The legend of the figure 1 should go into figure 5. The chemo-sensitivity results are to be reported in fig.5.

\- The legend of the figure 1 went into figure 5.

\- Define what is F1-F3 in the material and method.

\- Definition of F1-F3 was described in materials and methods.

\- Provide a table that show which PDX were injected subcutaneous and which ones were fat pad. Does that influence the success rate?

\- Only one tumor was subcutaneously implanted into mice. This PDX model was failed to establishment. It was too small to compare with PDX models which were implanted into fat pad.

\- More information should be provided about the how the cells were extracted from the tissue. Was there a brief culture? How many cells were injected subcutaneously or in the fat pad? Was matrigel used? Or did the authors really injected tissue as stated in their material and methods? in that case please provide the size of the tissue and how it was chosen.

\- When patients underwent breast surgery, tumor tissue was removed and immediately transferred to animal laboratory. Cubic tissue was minced and directly implanted into mice without delay. It was described in materials and methods.

\- Fig 3. Add a positive control for the staining presented and add Ki67

\- Positive control and ki67 were added in the figure 2B and 2C.

\- Table1 and table 2 have the same title. Clarify which cases were used for each table. If table 2 represent a subset of table 1, it must show in the title.

\- The title of table 1 was revised.

\- Fig5. The graph axis cannot be seen. Please state in the figure legend how many mice were used per group.

\- Three mouse were used per group. This is described in the legend of figure 4.

\- Please provide information on the treatment received by the patients for the neo-PDX. Can the authors see any correlation between the treatment and how fast or successfully the PDX grow?

\- Supplementary table 1 presented information on the treatment received by the patients. In successful establishment of PDX models from Neo TNBC patient, 6 of 9 patients received AC+taxane chemotherapy and 2 patients received gemcitabine+taxane, taxane chemotherapy. One patient received AC chemotherapy. We analyzed success rates according to treatment regimens. However, we found no correlated between them. For example, as you see the table 1A and 1B, there was no significant association between treatment group and PDX successful engraftment.

Table 1. Chi-square analysis of regimen in PDX models from patients who received neoadjuvant chemotherapy.

A. Analysis of AC+taxane based chemotherapy and others in PDX models from patients who received neoadjuvant chemotherapy.

PDX status

Failure (%) Success (%) p-value

AC+taxane based chemotherapy 22(73.3%) 5 (55.6%) 0.416

Others 8 (26.7%) 4 (44.4%)

B. Analysis of AC+taxane based, AC based chemotherapy and others in PDX models from patients who received neoadjuvant chemotherapy.

PDX status

Failure (%) Success (%) p-value

AC+taxane based chemotherapy 23 (76.7%) 5 (55.6%) 0.222

AC based chemotherapy 4 (13.3%) 1 (11.1%)

Others 3 (10%) 3 (33.3%)
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